for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

129.90USD

Change

0.70(+0.54%)

Volume

1,787,680

Today's Range

129.08

 - 

130.48

52 Week Range

122.00

 - 

148.97

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
129.20
Open
129.66
Volume
1,787,680
3M AVG Volume
165.32
Today's High
130.48
Today's Low
129.08
52 Week High
148.97
52 Week Low
122.00
Shares Out (MIL)
2,639.17
Market Cap (MIL)
340,980.20
Forward P/E
14.89
Dividend (Yield %)
2.94

Next Event

Dividend For JNJ.N - 0.9500 USD

Latest Developments

More

Actelion Pharmaceuticals - Announces New Data Evaluating Initial Combination Therapy With Opsumit And Tadalafil, A PDE5 Inhibitor

Janssen Says FDA Approves Stelara For Adults With Moderately To Severely Active Ulcerative Colitis

Johnson & Johnson Consumer Inc To Voluntarily Recall Single Lot Of Johnson's Baby Powder In U.S.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

1 Johnson And Johnson Plz

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

2.11 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

71.9K

2017

76.5K

2018

81.6K

2019(E)

82.1K
EPS (USD)

2016

6.730

2017

7.300

2018

8.180

2019(E)

8.676
Price To Earnings (TTM)
20.19
Price To Sales (TTM)
4.17
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
19.37
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

J&J slashes third-quarter profit by $3 billion over proposed opioid deal

Johnson & Johnson <JNJ.N> on Wednesday lowered its previously reported third-quarter profit by $3 billion to account for a proposed opioid settlement payment.

J&J says proposed opioid settlement to lower reported Q3 profit by $3 bln

Johnson & Johnson on Wednesday lowered its previously reported profit for the third quarter to $1.8 billion from $4.8 billion to account for a proposed opioid settlement payment.

Johnson & Johnson CEO testified Baby Powder was safe 13 days before FDA bombshell

Facing off against a plaintiff’s lawyer for the first time about Johnson & Johnson’s Baby Powder, the company’s Chief Executive Alex Gorsky earlier this month insisted that the company’s iconic brand was safe.

FDA alerts consumers of J&J baby powder recall, says it stands by tests

The U.S. Food & Drug Administration said on Friday that it found that a sample from one lot of Johnson & Johnson's baby powder contained chrysotile fibers, a type of asbestos, confirming test results the company disclosed earlier on Friday.

J&J recalls 33,000 bottles of baby powder as FDA finds asbestos in sample

Johnson & Johnson said on Friday it is recalling around 33,000 bottles of baby powder in the United States after U.S. health regulators found trace amounts of asbestos in samples taken from a bottle purchased online.

US STOCKS SNAPSHOT-Boeing, J&J pull down Wall Street along with weak China data

Wall Street fell on Friday as negative headlines about Johnson & Johnson and Boeing , along with bleak economic data from China, soured investor risk appetite and offset generally positive corporate earnings.

FDA alerts consumers of J&J baby powder recall, says it stands by tests

The U.S. Food & Drug Administration said on Friday that it found that a sample from one lot of Johnson & Johnson's baby powder contained chrysotile fibers, a type of asbestos, confirming test results the company disclosed earlier on Friday.

US STOCKS-Wall St pressured by J&J, Boeing; growth worries linger

* Indexes down: Dow 0.67%, S&P 500 0.43%, Nasdaq 0.97% (Updates to early afternoon)

US STOCKS-Wall Street pressured by J&J, global growth concerns

* Indexes off: Dow 0.28%, S&P 500 0.15%, Nasdaq 0.50% (Adds comments, updates market action)

US STOCKS SNAPSHOT-Wall St opens lower as J&J slips

U.S. stocks opened slightly lower on Friday, weighed down by Johnson & Johnson, while upbeat earnings reports limited losses and calmed nerves about the global economy after China expanded at its weakest pace in almost 30 years.

J&J to recall single lot of baby powder as FDA finds traces of asbestos

Johnson & Johnson said on Friday that it would recall a single lot of its baby powder in the United States after the Food and Drug Administration found trace amounts of asbestos in samples taken from a bottle purchased online.

J&J's depression drug Spravato wins European panel vote

Johnson & Johnson's nasal spray for depression won recommendation for approval from a European Medicines Agency (EMA) panel, the regulatory body said on Friday.

Johnson & Johnson agrees to pay about $117 million to settle U.S. states' mesh probe

Johnson & Johnson has agreed to pay nearly $117 million to resolve allegations that it deceptively marketed transvaginal surgical mesh devices, U.S. state attorneys general said on Thursday.

J&J agrees to pay about $117 mln to settle vaginal mesh litigation

U.S. state attorneys general said on Thursday that Johnson & Johnson and its unit had agreed to pay nearly $117 million to settle litigation over deceptive marketing of the company's transvaginal surgical mesh devices.

Missouri appeals court overturns $110 million Johnson & Johnson talc verdict

A Missouri appeals court overturned a $110 million verdict against Johnson & Johnson <JNJ.N> in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

Prescription drugs boost drives J&J forecasts higher, shares rise

Johnson & Johnson <JNJ.N> raised its full-year earnings forecast on Tuesday as it reported higher third-quarter sales of psoriasis treatment Stelara and cancer drug Imbruvica while attempting to alleviate investor concerns over mounting legal challenges.

US STOCKS SNAPSHOT-Wall St opens higher on upbeat start to earnings

U.S. stocks opened higher on Tuesday, as strong earnings reports from JPMorgan Chase, UnitedHealth and Johnson & Johnson allayed concerns about the fallout from a prolonged U.S.-China trade war on corporate America.

US STOCKS-Futures rise as third-quarter earnings start on strong note

U.S. stock index futures rose on Tuesday, as the third-quarter earnings season got off to an upbeat start with robust reports from JPMorgan Chase, UnitedHealth and Johnson & Johnson.

Johnson & Johnson posts 23% rise in third-quarter profit

Johnson & Johnson on Tuesday posted a 22.9% rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

Massive jury award against J&J highlights risks of its legal strategy

A jury award that hit Johnson & Johnson <JNJ.N> with $8 billion in punitive damages for a case involving its anti-psychotic drug Risperdal highlights the risks of the drugmaker's all-or-nothing legal strategy, several legal experts told Reuters on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up